Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.73 |
| ▸ | DRD3 | P35462 | 3/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31324598 | 1.00 | DRD2 (0.73) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL1786250 | 0.98 | DRD2 (0.71) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL8076233 | 0.86 | DRD2 (0.79) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL266921 | 0.86 | DRD2 (0.79) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL4210081 | 0.86 | DRD2 (0.79) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL895845 | 0.84 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL43366 | 0.84 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL4208502 | 0.84 | DRD2 (0.77) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL4213402 | 0.84 | DRD2 (0.77) | DRD2DRD3ADRA1ACHRM2CHRM1 | |
| SCHEMBL895742 | 0.84 | DRD2 (1.00) | DRD2DRD3ADRA1ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| EP-1018514-A1 | NF-$g(k)B INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0452390-B1 | HALO SUBSTITUTED AMINOTETRALINS | UPJOHN CO (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5225596-A | Halo substituted aminotetralins | THE UPJOHN COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0334538-B1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1992-12-02 | — | — | EP | disclosed |
| EP-0452390-A1 | HALO SUBSTITUTED AMINOTETRALINS. | UPJOHN CO (US) | 1991-10-23 | — | — | EP | disclosed |
| EP-0407416-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1991-01-16 | — | — | EP | disclosed |
| WO-1990007490-A1 | HALO SUBSTITUTED AMINOTETRALINS | THE UPJOHN COMPANY (US) | 1990-07-12 | — | — | WO | disclosed |
| WO-1989009050-A1 | THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES | THE UPJOHN COMPANY (US) | 1989-10-05 | — | — | WO | disclosed |
| EP-0334538-A1 | Therapeutically useful tetralin derivatives | THE UPJOHN COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | DRD2 1315/4885DRD3 1897/4885ADRA1A 1697/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | DRD2 178/4885DRD3 241/4885ADRA1A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.